Biocept Stock Price To Earnings To Growth
Biocept fundamentals help investors to digest information that contributes to Biocept's financial success or failures. It also enables traders to predict the movement of Biocept Stock. The fundamental analysis module provides a way to measure Biocept's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biocept stock.
Biocept |
Biocept Company Price To Earnings To Growth Analysis
Biocept's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Biocept Price To Earnings To Growth | (0.04) X |
Most of Biocept's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biocept is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Biocept has a Price To Earnings To Growth of -0.04 times. This is 105.63% lower than that of the Biotechnology sector and 98.27% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.82% higher than that of the company.
Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Biocept Fundamentals
| Return On Equity | -1.87 | |||
| Return On Asset | -0.52 | |||
| Operating Margin | (10.38) % | |||
| Current Valuation | 5.92 M | |||
| Shares Outstanding | 2.63 M | |||
| Shares Owned By Insiders | 9.20 % | |||
| Shares Owned By Institutions | 1.98 % | |||
| Number Of Shares Shorted | 29.73 K | |||
| Price To Earning | 5.34 X | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 0.20 X | |||
| Revenue | 25.86 M | |||
| Gross Profit | (2.58 M) | |||
| EBITDA | (31.98 M) | |||
| Net Income | (32.09 M) | |||
| Cash And Equivalents | 27.57 M | |||
| Cash Per Share | 1.63 X | |||
| Total Debt | 12.11 M | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 3.38 X | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (13.29 M) | |||
| Short Ratio | 0.05 X | |||
| Earnings Per Share | (48.17) X | |||
| Price To Earnings To Growth | (0.04) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 50 | |||
| Beta | 0.6 | |||
| Market Capitalization | 1.14 M | |||
| Total Asset | 30.87 M | |||
| Retained Earnings | (298.44 M) | |||
| Working Capital | 10.84 M | |||
| Current Asset | 9.64 M | |||
| Current Liabilities | 3.34 M | |||
| Z Score | -15.64 | |||
| Net Asset | 30.87 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Biocept Stock
If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |